in this issue
Chemical Week Magazine :: Newsbriefs
Bayer bids to acquire Norwegian pharma company
6:04 AM MST | December 6, 2013
The board of Algeta (Oslo) says it has received a preliminary acquisition proposal from Bayer. Bayer has offered to pay 336 Norwegian kroner ($54.68) per Algeta share, valuing the bid at $2.4 billion. Discussions are at an early stage, and further announcements may come, Algeta says. Bayer and Algeta are partners in Xofigo, which was approved by FDA in May for the treatment of castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. Xofigo is the first alpha particleâ€“emitting radioactive therapeutic agent...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee